Press Releases

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York .

– Grew 2018 revenue 16% year-over-year to $347 million , driven primarily by U.S. LINZESS ® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 13, 2019 .

– Important step toward launching two independent, publicly-traded companies – – Separation on track for first half 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the filing by Cyclerion Therapeutics, Inc.

– Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company – – Julie McHugh to serve as chair of Ironwood board; Marsha Fanucci to serve as chair of Cyclerion board – – Ironwood and Cyclerion expected to have annually elected directors and

– IW-6463 is one of five Cyclerion sGC stimulators following planned separation – – Data from Phase 1 study expected in second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2019-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 15, 2019-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable

– Dr. Shetzline will lead global product development for Ironwood following separation – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2019-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael Shetzline , M.D., Ph.D., will join Ironwood as chief medical officer, senior vice

– Mark Mallon to become CEO of Ironwood – – Peter Hecht , founder and current CEO of Ironwood, to become CEO of Cyclerion ( R&D Co. ) – – Separation on track for completion in first half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2019-- Ironwood Pharmaceuticals, Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2018 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time at the Westin St.

CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 2, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) and Allergan plc  (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th , 2018 at 2:15 p.m. Mountain Time ( 4:15 p.m.

– LINZESS ® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 – – Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan – – Received Fast Track Designation for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 6, 2018 . Individuals interested in participating in the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology

– Praliciguat Phase II trial in HFpEF continues to enroll patients with topline data expected in the second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.m.

TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 21, 2018-- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C